APA (7th ed.) Citation

GK, A., R, M., AP, V., AF, O., MS, B., M, L., . . . JD, G. (2020). Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. The oncologist, 25(12), e1837. https://doi.org/10.1634/theoncologist.2020-0093

Chicago Style (17th ed.) Citation

GK, Abou-Alfa, et al. "Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma." The Oncologist 25, no. 12 (2020): e1837. https://doi.org/10.1634/theoncologist.2020-0093.

MLA (9th ed.) Citation

GK, Abou-Alfa, et al. "Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma." The Oncologist, vol. 25, no. 12, 2020, p. e1837, https://doi.org/10.1634/theoncologist.2020-0093.